News & Updates
Filter by Specialty:
Upadacitinib delivers sustained PRO improvements in AD
Data presented at AAD 2023 underpin the potential of upadacitinib, a selective Janus kinase inhibitor, to provide long-term improvements in patient-reported outcomes (PROs; skin symptoms, sleep, and quality of life [QoL]) in individuals with moderate-to-severe atopic dermatitis (AD).
Upadacitinib delivers sustained PRO improvements in AD
10 Apr 2023
Preop hypertension, hypercholesterolemia foretell T2DM persistence after metabolic surgery
For patients with obesity and type 2 diabetes mellitus (T2DM) who are scheduled to undergo metabolic surgery, the presence of hypertension and hypercholesterolemia at baseline may predict failure of T2DM remission after the procedure, according to a study.
Preop hypertension, hypercholesterolemia foretell T2DM persistence after metabolic surgery
09 Apr 2023
Valaciclovir suppresses Epstein-Barr virus in COPD patients
Treatment with valaciclovir leads to efficacious suppression of Epstein-Barr virus (EBV), having the potential to reduce the sputum inflammatory cell infiltrate, in patients with chronic obstructive pulmonary disease (COPD), according to data from the EViSCO study.
Valaciclovir suppresses Epstein-Barr virus in COPD patients
08 Apr 2023
Systemic therapies effective in melanoma of unknown primary
Patients with melanoma of unknown primary (MUP) benefit from novel therapies similarly as those with stage-matched melanoma of known cutaneous primary (cMKP) despite having less favourable baseline prognostic factors, reveals a study.
